Havah is proud to announce that our CEO Kathy Harrsion is to be honoured at the Springboard Annual Gala Oct 20, 2021 In New York for her work in advancing Havah to a licensing deal with Clarus Pharma.
Havah has completed world leading pre-clinical and clinical trials (Phase I,II and III) to develop androgen-based pharmaceuticals for use in breast disease.
Havah is one of the first biotechs to utilize the breast tissue specific innate hormone/immune interface.
Androgens are an essential hormone in both men and women-the balance between estrogens and androgens is critical in the maintenance of hormonal homeostasis and the interface between hormonal function and the immune system.
Havah Therapeutics lead product delivers a unique androgen product to effect a beneficial tissue specific alteration in estrogen:androgen ratio and reduce breast tissue autoimmune inflammation
“As no approved female product is presently approved by a national regulatory body, the panel highlighted the pressing need for more research into testosterone therapy for women and the development and licensing of products indicated specifically for women.”
Founder and inventor, 30-year breast cancer specialist/surgeon and renowned medical innovator, clinical oncologist, widely published molecular oncologist in leading journals incl. Nature, founder/ pioneer of three leading (Australian) multi-disciplinary breast centres in both the public and private sectors. Dr Birrell, with his scientific research partner, Prof Wayne Tilley, are internationally recognized for pioneering the use of androgens in breast disease.
More than 25 years in biotechnology including 9 years in patent attorney practice. Leadership roles in biotech companies have included CEO of ASX listed Dimerix Ltd and current Director of Disruptive Nutrition Pty Ltd. Kathy has extensive experience in intellectual property strategy, commercial drug development strategy and achieving drug development milestones. Kathy’s qualifications in science, intellectual property law and governance provide the depth of skill to lead HAVAH through its next stage of growth.
Mr Martell is a biopharma entrepreneur with 30+ years experience founding, leading and managing companies. He has overseen numerous business development agreements and transactions worth billions of dollars. He is the President and CEO of Nuvelution Pharma. Before joining Nuvelution, he was Founder and Executive Chairman of Indapta and Chief Executive Officer of Achieve Life Sciences, where he led the merger of the company with Oncogenex. Prior to that, he held similar roles at Sevion, NeurogesX and Poniard Pharmaceuticals. Earlier in his career, Mr Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he was instrumental in deals with Bristol-Myers Squibb and Merck KGaA, and built ImClone Systems’ worldwide commercial operations and field sales force to market and commercialize Erbitux®. Before joining ImClone Systems, Mr Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company’s oncology franchise, including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin’s lymphoma. Mr Martell began his career at Roche Pharmaceuticals.
Joe Schacter, Business Development